Aug 13, 2026 earnings call — Proteus roadmap update and timeline change
Company updated Proteus launch to the second quarter of 2027 and added an extra instrument design cycle.
Key quotes
"We have updated the Proteus launch timeline from the end of 2026 to the second quarter of 2027."
"We believe that with this additional time, we will be in a strong position to deliver Proteus with a detection capability of either 19 or 20 amino acids at launch."
"As part of this disciplined approach, earlier today we announced operating expense actions, including a targeted reduction in force representing approximately 20% of the total company headcount."
Analyst Q&A 5
why extra design cycle
Q (Scott Henry · Alliance Global Partners): He asked whether the changes were driven by customers or by an internal decision, and how confident management is in the Q2 2027 target. He also asked who will be the early adopters and how R&D spending will trend near term.
A: Management said the change was driven by an internal assessment of repeatability, manufacturing and supply chain needs, not new customer requests. They completed a thorough review and added a design cycle to retire key risks and land on a Q2 2027 timeline. R&D spend will remain largely consistent with prior quarters with some adjustments.
"It wasn't driven by some sort of new feedback from customers that caused us to believe we need to add some capabilities we weren't planning for." — Jeffrey Hawkins (CEO)
extra cycle effect on early access
Q (Michael King · Rodman & Renshaw): He asked whether the extra design cycle came from prototype runs or from scale-up and how it affects the early access program. He also asked if reagents are affected, whether Platinum Pro units can be used, and the timing for a full amino acid reagent set.
A: Management said the cycle came from running integrated machines in R&D to assess repeatability and to add design-for-manufacturing changes. They said reagents and consumables have tracked to expectations and the change is very hardware-focused. Early access has not officially started and will move later; they can use Platinum Pro placements to engage customers, and now expect to launch with either 19 or 20 amino acids while demonstrating all 20 this year.
"With this shift in the timeline, we would expect that the early access will also move out." — Jeffrey Hawkins (CEO)
manufacturing time and supply risks
Q (Kyle Mikson · Canaccord Genuity): He asked how the extra design cycle will affect reproducibility and what steps will prevent lower performance. He also asked about production time, chip/GPU supply exposure, the non-human market, AI interest, and timing of the $12 million OpEx savings.
A: Management said some internal units already exceed specs while others are at or below, and the design changes aim to make all units perform consistently above their internal specifications. They said building machines has been more challenging and longer than anticipated, but the manufacturability improvements should compress build time and increase yield; they are watching long-lead components like GPUs and can stockpile as needed. They also said Platinum gave them real customer insight into non-human markets and that there is market and AI interest; the OpEx savings will start to show in the fourth quarter and total $12 million annualized when fully implemented.
"It has definitely been more challenging and sort of longer to get the machines than we had anticipated." — Jeffrey Hawkins (CEO)
steps before Q2 2027 launch
Q (Charles Wallace · H.C. Wainwright): He asked what the specific gating items are between now and Q2 2027 and what new items were added versus the prior plan. He also asked whether the company still plans an early access program and when that would occur.
A: Management said the main gating item is the added instrument design cycle: finalize design changes, build machines, test them and confirm performance over the remainder of this year. They will then combine instruments with reagents and consumables in the first half of 2027 toward a Q2 launch. Early access has not started and would occur after the cycle completes, likely end of this year or early 2027, with sample evaluation possible before a deployed early access.
"We expect to work through that cycle of finalize the design, build, test and confirm performance over the course of the remainder of this year." — Jeffrey Hawkins (CEO)
non-human market and amino coverage
Q (Michael Okunewitch · Maxim Group): He asked how mature and ready the non-human proteomics market is for Proteus and whether published academic work is needed first. He also asked whether capturing 17–18 amino acids versus the full 20 gives incremental benefits or opens new applications.
A: Management said pathogen research and agricultural markets are already using Platinum devices and are ready today for the technology, while other non-human areas need more direct customer work. On amino coverage, they said the move from 18 to 19 or 20 mainly reaches lower-abundance amino acids; many applications see little difference, but deep protein profiling may require all 20 and full coverage simplifies customer conversations and sales.
"So we believe those markets are absolutely ready for the technology." — Jeffrey Hawkins (CEO)